Europe's regulator backs Mounjaro for children aged 10 and older

The European Medicines Agency's committee recommended on Dec. 12 that Eli Lilly's tirzepatide, sold in Europe as Mounjaro, be approved to treat type 2 diabetes in children and adolescents aged 10 and older ^[1]. The recommendation would extend a drug already approved for adults with type 2 diabetes and for weight loss to a much younger group of patients ^[1].

Until now, treatment choices for children with type 2 diabetes have been limited mainly to metformin and insulin ^[1]. The committee's recommendation would allow Mounjaro to be used on its own in children when metformin is not appropriate because of intolerance or contraindications, or as an add-on to other diabetes medicines ^[1].

The recommendation is based on a late-stage clinical trial that found Mounjaro helped children and adolescents aged 10 to 17 with type 2 diabetes manage their blood sugar and lose weight ^[1]. Lilly and its rival Novo Nordisk have both been studying their GLP-1 drugs in younger patients ^[1]. Novo's older GLP-1 drug, Victoza, is already approved in children 10 and older with type 2 diabetes, and the company's Wegovy is used for weight loss in children 12 and older ^[1].

Why it matters for patients

For families managing a child's type 2 diabetes, the shift matters because it would add a new tool beyond metformin and insulin, the two options that have been available for years ^[1]. Type 2 diabetes in children is harder to treat than in adults in some respects, and having fewer approved medicines has meant fewer choices when a first-line drug does not work or cannot be tolerated ^[1].

The committee's recommendation is specific about how the drug could be used: as a standalone option only when metformin is ruled out, or alongside other diabetes medicines ^[1]. That detail matters for parents and doctors deciding on a treatment plan, since it is not a blanket clearance for any child with type 2 diabetes but a more targeted expansion ^[1].

It is also worth noting this recommendation covers type 2 diabetes, not weight loss on its own, in this age group ^[1]. Novo's Wegovy already has a separate weight-loss approval for children 12 and older, showing that different GLP-1 drugs currently have different approved uses depending on age and condition ^[1].

The source material does not detail what a similar action by the U.S. Food and Drug Administration would look like or when it might take effect, so those specifics are not yet known from what is available here.

What happens next

The EMA committee's recommendation is not a final approval. In the EU regulatory process, the European Commission typically reviews such committee recommendations before granting a formal marketing authorization, though the source does not specify a date for that next step ^[1]. Parents and clinicians in Europe will likely be watching for that formal decision, while questions about equivalent U.S. approval, including timing and terms, remain outside what this reporting confirms ^[1].